Editas Medicine, Inc. key statistics and ratios

In fiscal 2025, Editas Medicine, Inc. had return on equity of -198.1%, an operating margin of -394.9%, debt equal to 214.8% of equity and a current ratio of 3.54. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Editas Medicine, Inc.: financial ratios, annual
Fiscal year	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Operating margin	<−999%	−873.6%	−356.1%	−686.4%	−148.6%	−756.1%	<−999%	−216.6%	−777.2%	−394.9%	−161.4%
Net margin	<−999%	−876.5%	−344.3%	−651.4%	−127.8%	−753.6%	<−999%	−196.1%	−733.7%	−395.0%	−157.3%
Free-cash-flow margin	−887.8%	−83.6%	−158.0%	−228.1%	−206.1%	−672.5%	−920.6%	−175.2%	−678.1%	−409.3%	−256.5%
Return on equity	−72.2%	−70.2%	−49.5%	−53.6%	−35.4%	−40.6%	−48.2%	−43.2%	−98.1%	−198.1%	−111.6%
Return on assets	−42.4%	−39.9%	−27.7%	−28.8%	−21.4%	−30.8%	−37.0%	−30.2%	−56.4%	−60.6%	−34.9%
Asset turnover	0.03	0.05	0.08	0.04	0.17	0.04	0.03	0.15	0.08	0.15	0.22
Current ratio	5.66	9.05	10.44	7.74	7.20	10.82	5.93	5.39	3.75	3.54	3.19
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	42.8%	214.8%	52.9%
Interest cover (operating income ÷ interest)	—	—	—	—	—	—	—	—	—	n/m	n/m
R&D as % of revenue	941.3%	605.8%	283.9%	472.0%	174.1%	557.9%	887.6%	227.4%	616.6%	222.0%	180.7%
Capital spending as % of revenue	57.7%	15.0%	14.9%	30.0%	7.9%	31.2%	20.9%	6.0%	27.3%	1.5%	1.5%

US$ thousands unless shown otherwise. Fiscal quarters.

Editas Medicine, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Operating margin	<−999%	−152.2%	<−999%	<−999%	−325.4%	−31.3%	−883.2%	−156.0%
Net margin	<−999%	−148.3%	<−999%	<−999%	−333.0%	−22.7%	−882.4%	−153.3%
Free-cash-flow margin	<−999%	−167.6%	<−999%	<−999%	−414.6%	−147.3%	−817.8%	−249.6%
Current ratio	3.75	3.75	3.08	2.77	2.86	3.54	3.22	3.19
Debt to equity	—	42.8%	87.4%	295.3%	439.1%	214.8%	>999%	52.9%
R&D as % of revenue	>999%	158.8%	570.9%	452.2%	262.2%	110.8%	621.7%	169.7%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 6 checks passed · June 30, 2026

What it owns · $237m

Short-term assets $218mLonger-term assets $19m

What it owes, and who funded it · $237m

Short-term liabilities $68mLonger-term liabilities $64mShareholders' equity $105m

Short-term assets cover short-term liabilities $218m of assets due within a year against $68m of liabilities due within a year.
Short-term assets cover long-term liabilities $218m short-term assets against $64m of longer-dated liabilities.
More cash than debt $182m of cash against $56m of debt.
Debt below 40% of shareholders' equity Debt is 53% of equity.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt −$120m of operating cash flow against $56m of debt.
Operating profit covers interest at least five times over Operating income of −$76m against $4m of interest.

From Editas Medicine, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

8 /100

Weak moat

How hard Editas Medicine's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -31.9% of total assets over 10 years.
Durability 10 / 20

Operating margin has been a median -466.1%; its worst year was -1118.4%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 9 years, at a median -263.2% of revenue.
Discipline 0 / 20

The diluted share count rose 56.6% over five years; stock-based pay has been a median 75.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: EDIT vs SPRO EDIT vs STRO EDIT vs OCUL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Editas Medicine, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Editas Medicine, Inc.